Core Viewpoint - USANA Health Sciences, Inc. has updated the timing for the release of its third quarter 2025 financial results, moving it from October 21, 2025, to October 22, 2025, after market close [1] Financial Results Announcement - The company will report its third quarter 2025 financial results after the market closes on October 22, 2025, instead of the previously scheduled date of October 21, 2025 [1]

Core Insights - USANA's Vitamin D supplement has received the ConsumerLab.com Seal of Approval, indicating its purity, potency, and scientific precision [1][2] - Approximately 42% of adults in the U.S. are vitamin D deficient, highlighting the importance of reliable supplements in the market [1] - The supplement contains 2000 IU of vitamin D3 per tablet, exceeding current recommendations by more than four times [7] Product Quality and Testing - The approval from ConsumerLab.com reflects USANA's commitment to transparency, quality, and precision in its products [2][3] - The Vitamin D supplement underwent rigorous testing for potency, purity, and label accuracy, ensuring it delivers 100% of the claimed amounts of vitamin D3 and vitamin K [2] - USANA's internal standards align with the benchmarks required for the Seal of Approval, emphasizing the company's dedication to high-quality products [2][3] Scientific Backing and Benefits - The Vitamin D supplement is designed to support bone strength, immune defense, and nutrient absorption [3] - USANA continues to invest in research, manufacturing, and testing protocols to maintain its position as an industry leader in nutritional science [4] Company Overview - USANA has been providing premium-quality nutrition and lifestyle products for over 30 years, with a focus on empowering healthier living [6] - The company manufactures its award-winning supplements in an FDA-registered facility, ensuring high standards of quality [6]

Core Insights - USANA Health Sciences Inc. reported preliminary earnings for Q3 2025, leading to an initial share price decline of approximately 11% [1] Financial Performance - The company is currently undergoing a transitional period, which has affected investor sentiment [1] Company Background - USANA operates in the health sciences sector, focusing on nutritional products and dietary supplements [1]

Company Performance - Apogee Enterprises Inc. reported better-than-expected second-quarter financial results, with shares gaining 1.4% to $42.00 in after-hours trading [2] - Levi Strauss & Co. reported third-quarter earnings of 34 cents per share, exceeding the analyst consensus estimate of 31 cents per share, and quarterly sales of $1.543 billion, surpassing the estimate of $1.501 billion; however, shares fell 7.7% to $22.65 in after-hours trading [2] - VolitionRX Ltd. announced a public offering of common stock and common stock warrants, leading to a 20% dip in shares to $0.48 in after-hours trading [2] - USANA Health Sciences Inc. reported preliminary third-quarter results with an adjusted loss of 15 cents per share and sales of $214.00 million, resulting in an 11.4% decline in shares to $23.26 in after-hours trading [2] - Nurix Therapeutics Inc. reported worse-than-expected third-quarter financial results, causing shares to fall 5.7% to $10.24 in after-hours trading [2]

Preliminary Third Quarter 2025 Results Overview [Summary of Financial Performance](index=1&type=section&id=Summary%20of%20Financial%20Performance) USANA reported preliminary Q3 2025 net sales of $214 million, but a net loss of ($6.5) million and diluted EPS of ($0.36), with a 471% effective tax rate Q3 2025 Preliminary Financial Highlights vs Q3 2024 | Metric | Q3 2025 Preliminary | Q3 2024 | Change (YoY) | | :------------------------ | :-------------------- | :-------------- | :----------- | | Net sales | $214 million | $200 million | +$14 million | | Earnings from operations | $1.2 million | $15.6 million | -$14.4 million | | Operating Margin | 0.6% | 7.8% | -7.2% pts | | Net (loss) earnings | ($6.5) million | $10.6 million | -$17.1 million | | Diluted EPS | ($0.36) | $0.56 | -$0.92 | | Effective income tax rate | 471% | 43% | +428% pts | | Adjusted Diluted EPS | ($0.15) | $0.56 | -$0.71 | | Adjusted EBITDA | $13.8 million | $24.6 million | -$10.8 million | - The effective income tax rate for Q3 2025 significantly increased to **471%** from **43%** in Q3 2024, primarily due to lower than expected earnings coupled with the concentration of operating and administrative expenses in the United States[4](index=4&type=chunk)[5](index=5&type=chunk)[6](index=6&type=chunk) [Management Commentary on Performance and Strategy](index=1&type=section&id=Management%20Commentary%20on%20Performance%20and%20Strategy) Management noted Q3 operating results were below expectations due to softer sales and Brand Partner productivity, but remains confident in long-term strategy - Third quarter operating results came in below expectations, primarily due to softer-than-expected sales and Brand Partner productivity during the rollout of the enhanced Brand Partner compensation plan, and softer sales for Hiya due to lower customer acquisition rates[2](index=2&type=chunk) - Despite short-term challenges, the enhanced compensation plan is viewed as a strategic move for long-term success, with encouraging Brand Partner response and recent pickup in sales activity. Hiya is still expected to generate **double-digit sales growth for 2025**[2](index=2&type=chunk)[3](index=3&type=chunk) [CFO's Commentary and Outlook](index=2&type=section&id=CFO%27s%20Commentary%20and%20Outlook) CFO highlighted Q3 profitability challenges from softer sales and increased tax rate, expecting full-year sales at the lower end of outlook and EPS below range - Profitability challenges in Q3 included softer sales, meaningful investments in the enhanced Brand Partner compensation plan, and a disproportionate increase in the estimated annual effective income tax rate from **45% to 65%** (**471% for Q3 2025**)[4](index=4&type=chunk) - For the full year, sales are expected to be at or near the lower end of the previously issued outlook range, and earnings per share are expected to be below the range, starting from a lower base of active customer counts in Q4. The company plans to align costs with operating performance to achieve a meaningfully lower tax rate in future years[5](index=5&type=chunk) [Upcoming Earnings Release and Conference Call](index=3&type=section&id=Upcoming%20Earnings%20Release%20and%20Conference%20Call) Final Q3 results are scheduled for release on October 21, 2025, with a conference call for analysts on October 22, 2025 - Final results for the third quarter are expected to be released after the close of market on **Tuesday, October 21, 2025**[7](index=7&type=chunk) - A conference call to discuss the announcement with analysts and institutional investors will be held on **Wednesday, October 22, 2025, at 11:00 a.m. Eastern Time**[7](index=7&type=chunk) Non-GAAP Financial Measures [Definition and Purpose](index=3&type=section&id=Definition%20and%20Purpose) This section defines non-GAAP measures like Adjusted EBITDA and Adjusted diluted EPS, used by management for internal assessment but not as GAAP substitutes - Adjusted EBITDA and Adjusted diluted EPS are non-GAAP financial measures used by management to internally reflect how the Company measures the business[9](index=9&type=chunk)[10](index=10&type=chunk)[15](index=15&type=chunk) - Non-GAAP financial measures have limitations, lack standardized meaning, and should not be considered in isolation from, or as a substitute for, GAAP financial information[16](index=16&type=chunk) [Reconciliation of Net (Loss) Earnings to Adjusted EBITDA](index=5&type=section&id=Reconciliation%20of%20Net%20%28Loss%29%20Earnings%20to%20Adjusted%20EBITDA) This section provides a reconciliation of GAAP Net (loss) earnings to Adjusted EBITDA, detailing adjustments for taxes, interest, depreciation, amortization, and acquisition costs Reconciliation of Net (Loss) Earnings (GAAP) to Adjusted EBITDA (non-GAAP) (in thousands USD) | | Quarter Ended | | Nine Months Ended | | | --- | --- | --- | --- | --- | | | Q3 2025 | Q3 2024 | YTD Sep-25 | YTD Sep-24 | | | September 27, 2025 | September 28, 2024 | September 27, 2025 | September 28, 2024 | | Net (loss) earnings attributable to USANA (GAAP) | $ (6,522) | $ 10,607 | $ 12,535 | $ 37,576 | | Net (loss) earnings attributable to noncontrolling interest | (140) | - | 537 | - | | Net (loss) earnings | $ (6,662) | $ 10,607 | $ 13,072 | $ 37,576 | | Adjustments: | | | | | | Income taxes | 8,456 | 8,001 | 24,278 | 28,346 | | Interest (income) expense | (529) | (3,093) | (1,201) | (8,429) | | Depreciation and amortization | 5,112 | 5,559 | 16,050 | 16,345 | | Amortization of intangible assets - Hiya | 4,455 | - | 13,366 | - | | Earnings before interest, taxes, depreciation, and amortization (EBITDA) | 10,832 | 21,074 | 65,565 | 73,838 | | Add EBITDA adjustments: | | | | | | Non-cash share-based compensation | 3,576 | 3,542 | 10,078 | 10,945 | | Transaction, integration and transition costs - Hiya | 179 | - | 871 | - | | Inventory step-up - Hiya | - | - | 1,126 | - | | Consolidated adjusted EBITDA | 14,587 | 24,616 | 77,640 | 84,783 | | Less: Adjusted EBITDA attributable to noncontrolling interest | (804) | - | (3,604) | - | | Adjusted EBITDA attributable to USANA | $ 13,783 | $ 24,616 | $ 74,036 | $ 84,783 | [Reconciliation of Diluted (Loss) Earnings Per Share to Adjusted Diluted (Loss) Earnings Per Share](index=6&type=section&id=Reconciliation%20of%20Diluted%20%28Loss%29%20Earnings%20Per%20Share%20to%20Adjusted%20Diluted%20%28Loss%29%20Earnings%20Per%20Share) This section reconciles GAAP Diluted (Loss) EPS to Adjusted Diluted (Loss) EPS, detailing adjustments for Hiya acquisition costs, intangible asset amortization, and tax effects Reconciliation of Diluted (Loss) Earnings Per Share (GAAP) to Adjusted Diluted (Loss) Earnings Per Share (non-GAAP) (in thousands USD, except per share data) | | Quarter Ended | | | Nine Months Ended | | --- | --- | --- | --- | --- | | | September 27, 2025 | September 28, 2024 | September 27, 2025 | September 28, 2024 | | Net (loss) earnings attributable to USANA (GAAP) | $ (6,522) | $ 10,607 | $ 12,535 | $ 37,576 | | Earnings (loss) per common share - Diluted (GAAP) | $ (0.36) | $ 0.56 | $ 0.67 | $ 1.96 | | Weighted average common shares outstanding - Diluted | 18,293 | 19,083 | 18,671 | 19,181 | | Adjustment to net (loss) earnings: | | | | | | Transaction, integration and transition costs - Hiya | $ 179 | $ - | $ 871 | $ - | | Inventory step-up - Hiya | - | - | 1,126 | - | | Amortization of intangible assets - Hiya | 4,455 | - | 13,366 | - | | Adjustments to net (loss) earnings attributable to noncontrolling interest | (941) | - | (3,066) | - | | Income tax effect of adjustments to net (loss) earnings | - | - | (4) | - | | Adjusted net (loss) earnings attributable to USANA | $ (2,829) | $ 10,607 | $ 24,828 | $ 37,576 | | Adjusted (loss) earnings per common share - Diluted | $ (0.15) | $ 0.56 | $ 1.33 | $ 1.96 | | Weighted average common shares outstanding - Diluted | 18,293 | 19,083 | 18,671 | 19,181 | Company Information [About USANA Health Sciences](index=8&type=section&id=About%20USANA%20Health%20Sciences) USANA develops and manufactures nutritional supplements and personal care products, sold directly, and holds a **78.8%** stake in Hiya Health Products - USANA develops and manufactures high-quality nutritional supplements, functional foods, and personal care products, sold directly to Brand Partners and Preferred Customers in various global markets[21](index=21&type=chunk) - USANA owns a **78.8%** controlling ownership stake in Hiya Health Products, a children's health and wellness company[21](index=21&type=chunk) [Safe Harbor Statement](index=7&type=section&id=Safe%20Harbor%20Statement) This statement clarifies that the press release contains forward-looking statements subject to risks and uncertainties, including economic conditions and regulatory changes - The press release contains forward-looking statements based on current plans, expectations, estimates, forecasts, and projections, which involve a number of risks and uncertainties that could cause actual results to differ materially[19](index=19&type=chunk) - Key risks include global economic conditions, reliance on independent Brand Partners, effectiveness of compensation plans, governmental regulation, geopolitical relations, data privacy, and the integration of the Hiya acquisition[19](index=19&type=chunk)[20](index=20&type=chunk) [Investor and Media Contacts](index=8&type=section&id=Investor%20and%20Media%20Contacts) Contact information for investor relations and media inquiries is provided - Investor Relations Contact: **Andrew Masuda**, (801) 954-7201, investor.relations@usanainc.com[22](index=22&type=chunk) - Media Contact: **Sarah Searle**, (801) 954-7626, media@usanainc.com[22](index=22&type=chunk)

, /PRNewswire/ -- USANA (NYSE:USNA) is proud to announce that its chief scientific officer, Dr. Kathryn Armstrong, has received the Women Tech Award from the Women Tech Council of Utah. Dr. Kathryn Armstrong named a "Leadership Excellence Award" winner Dr. Kathryn Armstrong Dr. Kathryn Armstrong receives the Leadership Excellence Award from the Women in Tech Council The Women Tech Award is a distinguished recognition platform that celebrates women who are significantly contributing to the expansion and inno ...

Core Insights - The article emphasizes the importance of service as a means to enhance emotional wellness, particularly for leaders, highlighting that serving others can lead to emotional regulation and focus on what truly matters [1][2][3] Company Overview - USANA Health Sciences (NYSE: USNA) is recognized as a global leader in health and wellness products, emphasizing the significance of social wellness in building a successful business since its founding in 1992 [9] Leadership and Emotional Wellness - Kevin Guest, executive chairman of USANA, advocates that giving back is essential for leaders, as it fosters emotional strength through outward compassion [2][3] - Guest shares that service acts can disrupt negative thinking, restore clarity, energize the giver, reshape emotional patterns, ground identity, and strengthen team bonds [7] Philanthropy and Community Impact - All proceeds from Guest's book "All the Right Reasons" benefit the USANA Foundation, which has provided over 112 million meals to impoverished children and families [8]

Core Insights - USANA Health Sciences, Inc. has launched an upgraded Celavive skincare line featuring refreshed formulations and five new products [2] - The new product line includes a Vitalizing Serum, a Bi-Phase Makeup Remover, a Contouring Face & Neck Crème, and an improved Triple Action Eye Cream [3] - The company has hired two seasoned beauty educators as global brand ambassadors to enhance Celavive's presence in Asia and other key international markets [4] Company Overview - USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products across the Asia Pacific, the Americas, and Europe [5] - The company is recognized as one of the best debt-free stocks [5]

Core Insights - USANA has launched an upgraded version of its Celavive skincare brand, featuring new products and enhanced formulas aimed at achieving youthful and radiant skin [1][3]. Product Innovations - The Celavive Vitalizing Serum now contains over four times the active ingredients, including BioPeptide-CS, Olivol24™, CoQ10, and plant-based Bakuchiol, promoting collagen synthesis and skin radiance [4]. - The Celavive Bi-Phase Makeup Remover is a new lightweight formula that cleanses and conditions the skin, infused with cucumber fruit complex for a soothing effect [5]. - The Celavive Contouring Face & Neck Crème is designed for women aged 35 and above, featuring Feminage™, which supports skin elasticity and smoothness [6]. - The Celavive Triple Action Eye Cream has nearly ten times more active ingredients than its predecessor, targeting fine lines, puffiness, and dark circles [7]. - The Celavive Perfecting Toner has been upgraded to balance pH, boost hydration, and refine skin texture, utilizing a blend of peptides, botanicals, and antioxidants [8]. Brand Ambassadors - USANA has appointed Joy Tan and Violet Chan as global ambassadors for the Celavive brand, leveraging their extensive experience in beauty education to enhance brand engagement [9][10].

Core Insights - USANA has announced advancements to its Nutritionals product line, including enhanced versions of existing products and new offerings aimed at improving global health and wellness practices [1][2][3] New and Upgraded Products - **CellSentials**: Now includes pyrroloquinoline quinone (PQQ) in its InCelligence Complex, supporting mitochondrial biogenesis and cognitive function [3] - **Core Aminos**: A comprehensive essential amino acid formula with HMB, designed for muscle retention and recovery, suitable for athletes and older adults [3] - **Circulate+**: An orange-flavored drink powder that promotes heart health using red spinach extract, vitamin C, and L-Arginine to aid nitric oxide production [3] - **Proflavanol**: Enhanced with a variety of flavonoids for broad antioxidant support, promoting heart health, immune support, and healthy aging [3] - **Marine Collagen Peptides**: A ready-to-drink supplement containing 4.8 grams of marine collagen for skin and joint health, designed for convenience [3] - **BiOmega**: An upcoming omega-3 supplement in triglyceride form for improved bioavailability, containing concentrated EPA and DHA [3] Company Overview - USANA is recognized for its quality nutritional and lifestyle products, with over 30 years of experience and adherence to strict Good Manufacturing Practices in its FDA-registered facility [5]